Extracorporeal Membrane Oxygenation Machine Market Size, Share, & Trends Analysis Report By Component, By Modality (VA, VV, AV) By Patient Type, By Application, By Region And Segment Forecasts, 2023 - 2030

Report Overview

The global extracorporeal membrane oxygenation machine market size was valued at USD 294.2 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.4% during the forecast period. The key drivers of the market are rising incidence of cardiopulmonary disease and respiratory failure. According to Centers for Disease Control and Prevention (CDC), an individual dies every 37 seconds from cardiovascular disease in the U.S. Furthermore, chronic obstructive pulmonary disease (COPD) was among the leading causes of death in the U.S in 2018. The increasing adoption rate of extracorporeal membrane oxygenation machine (ECMO) has stimulated technological advancement in these systems. The advancement includes introduction of hollow pumps, oxygenators and heparin coated cannula used in various applications in surgeries.

The increasing number of hospitals offering ECMO services and rising number of awareness programs are some of the factors boosting the market growth. The adoption of ECMO machines in hospitals has been increased significantly. According to Extracorporeal Life Support Organization (ELSO), the number of hospitals offering ECMO services reached 264 in 2019 up from 108 in 2008. ECMO devices are being used in the treatment of serious COVID-19 patients. However, other applications of these devices, including heart procedures showed sharp decline in 2020.

Increasing awareness about ECMO procedures and technological advancement is further propelling the market growth. Many government organizations aimed to create awareness about ECMO Procedures. Initiatives such as Global Initiative for Chronic Obstructive Lung Disease (GOLD) aim at creating awareness about COPD along with its treatment, which includes the usage of ECMO devices. Furthermore, the increasing adoption rate of ECMO machines is catalyzing technological advancement in these systems. The latest advancement includes oxygenators, hollow pumps, and heparin coated cannula used for various applications in surgeries. In addition, recently developed ECMO machines are smaller in size, thus increasing their portability and applications. Portable adaptors and compact ECMO machine circuits have also been developed which helps in transportation of critically ill patients.

Increasing geriatric population coupled with increasing incidence of coronary heart disease is boosting the adoption of ECMO machines. Coronary heart disease is strongly associated with age and is one of the leading causes of death worldwide. According to the United Nations, the number of people aged 80 years, or more is projected to reach 426 million by 2050 from 143 million in 2019 globally. However, complications associated with ECMO machines such as infections, technical failure, bleeding, and high cost of treatment may hinder the market.

Component Insight

Oxygenators segment accounted for the largest market share of 34.4% in 2022 and is expected to grow at a lucrative rate during the forecast period. The large market size of oxygenator is primarily attributed to its high cost and acute exchange rate for different system. The exchange rate of oxygenator is mainly due to mechanical failure, pump head thrombosis, and acute oxygenator thrombosis.

Pumps segment also has considerable market share owing to high cost and usage. The pumps in ECMO machines help pump blood from a patient to artificial lungs that send the blood back to the patient after oxygenation. The growth of the segment is primarily attributed to its high usage of pumps in ECMO procedures and availability of various types of pumps such as roller, impeller, and centrifugal. These pumps are used in various applications of ECMO procedures according to their need.

Modality Insight

Veno-arterial segment accounted for the largest market share of 42.0% in 2022 and is expected to grow at a lucrative CAGR during the forecast period. The largest size of the segment is primarily attributed to its high usage in treating patients with cardiac arrest, assisting with algorithm life support strategies to restore blood circulation.

Veno-venous segment captured significant share in 2022 and is expected to grow at a lucrative growth rate during the forecast period. The primary function of the veno-venous ECMO (VV ECMO) circuit is to ease the process of exchange of oxygen and carbon dioxide. Thus, it’s a major application in cases where lung support is needed. The key drivers of the market are the increasing incidence of chronic obstruction pulmonary disease. According to the WHO, there were 251 million cases of COPD globally in 2016 and this number is expected grow further over the forecast period.

Patient Type

Adult patient segment accounted for the largest market share of 59.2% in 2022 and is also expected to grow at a fastest rate during the forecast period. Consumption of alcohol, tobacco, and smoking coupled with sedentary lifestyle are increasing the global burden of cardiac and respiratory diseases in adults. According to the report published by the Extracorporeal Life Support Organization, in January 2016, there were around 7,850 number of adults suffering from cardiac illnesses that required ECMO.

Pediatric segment also accounted for the considerable market share and is expected to grow at a robust pace during the forecast period. The key drivers of the segment are increasing number of children with various pulmonary heart diseases. According to Extracorporeal Life Support Organization, in January 2016, around 8,102 children suffered from cardiac illness and required ECMO therapy.

By Application Insight

Respiratory segment accounted for the largest market share of 45.0% in 2022. The key market drivers include increasing prevalence of respiratory disorder and rising awareness of ECMO procedures. According to statistics published by the ELSO, over 2,600 patients suffering from respiratory illnesses in the U.S. underwent ECMO therapy in 2015.

Cardiac surgery segment also accounted for the considerable market share in 2022 owing to increasing incidence of cardiac surgery and rising awareness about ECMO machines in cardiac surgery. According to American Heart Association, approximately 1 of every 3 deaths in U.S. were caused by cardiovascular disease in 2016. Moreover, increasing the cost of ECMO procedures, especially in cardiac surgery is expected to drive the market. According to a study, the total direct medical costs of cardiovascular diseases are expected to reach USD 749 million by 2035.

By Regional Insights

North America dominated the market with share of around 39.6% in 2022 owing to the presence of major players and product launches. The growth of this market in the region can be attributed to the government support for quality healthcare, high purchasing power parity, and the increasing prevalence of diseases such as chronic obstructive pulmonary disease in the U.S. and Canada. The presence of sophisticated healthcare facilities and favorable reimbursement policies has led to increased hospital admission rate which in turn is expected to boost the usage rates in this region.

Asia-Pacific extracorporeal membrane oxygenation machine market is expected to witness the fastest growth during the forecast period. Key factors driving the growth of this region are the increase in healthcare expenditure by the government and private agencies in order to improve healthcare facilities. Economic development in countries such as Japan, India, and China coupled with rising government initiatives related to the development of healthcare infrastructure and reimbursement policies are further expected to augment the market growth.

Key Companies & Market Share Insights

Major players are focused on technological collaboration and product launches. For instance, in January 2019, Terumo Cardiovascular Systems Corporation introduces its smallest, lowest prime volume, full size adult Oxygenator, the Capiox NX19 with Ultraprime technology. The significant features of this device are minimized inflammatory response and high efficiency in micremboli removal. Thus, such launches deliver better performance and support market growth. Some of the prominent players dominating the ECMO machine market include:

• Medtronic plc

• Sorin Group

• Terumo Cardiovascular Systems Corporation

• MAQUET Holding B.V. & Co. KG

• Medos Medizintechnik AG

• Nipro Medical Corporation

• Microport Scientific Corporation

Recent Developments

• In May 2023, Medtronic successfully received FDA approval for its Micra AV2 and VR2 industry-leading leadless, miniaturized pacing systems. These are the smallest pacemakers in the world and offer extended battery life and more convenient programming compared to prior versions. The Micra AV2 also comprises exceptional algorithms that auto-program AV synchrony and coordinate the upper and lower chambers of the heart.

• In March 2023, Getinge received premarket FDA approval for its covered stent system- iCast in the US. iCast is used for the treatment of individuals with iliac arterial occlusive disease. The iCast covered stent system (sold outside the US as Advanta V12 covered stent), has been adopted for 20 years and is the world’s most clinically assessed balloon expandable polytetrafluoroethylene (ePTFE)-covered stent.

• In January 2023, CytoSorbents Corporation, one of the world leaders in the treatment of life-threatening conditions, announced that it had received approval from Health Canada to permit the inclusion of Canada-based sites in the randomized controlled trial of pivotal Safe and Timely Antithrombotic Removal – Ticagrelor (STAR-T). STAR-T was planned to offer definitive evidence of whether the DrugSorb-ATR system can successfully eliminate ticagrelor during surgery and enhance the outcomes by limiting bleeding.

• In January 2023, Getinge entered into a strategic partnership with kinderherzen, a Swedish non-profit organization, to help children battling with congenital heart defects. The company delivered numerous medtech products to support kinderherzen in its mission to develop a mobile cardiac surgery unit to provide treatment to children with congenital heart defects.

• In November 2022, LivaNova PLC announced that it received 510(k) clearance for ECMO from the FDA for LifeSPARC. LifeSPARC is the company’s next-gen Advanced Circulatory Support (ACS) pump & controller system.  This system helps simplify ECMO to make sure that hospitals of all types and sizes have access to a high level of life support.

• In October 2022, Eurosets, one of the leading companies in the design, production, and marketing of innovative medical devices, announced the market launch of Colibrì, the lightest life-saving system that is able to temporarily replace cardiac & pulmonary functions in adults, neonatal, and pediatric patients. Colibri is helpful during critical rescue operations. It is equipped with a special backpack with a barycentric hook that enables it to be transported via air, i.e., by drone or helicopter.

• In October 2021, MicroPort announced the acquisition of Hemovent GmbH, a Germany-based ECLS company for an overall cash consideration of over €123 million. Hemovent, specializes in the manufacturing of unconventional Extracorporeal Life Support (ECLS) systems, often termed Extracorporeal Membrane Oxygenation (ECMO). MOBYBOX system, the flagship product of the company has set a benchmark for ECMO devices in terms of convenience and mobility. This system offers timely life support in extracorporeal application to an enormous number of patients in life-threatening conditions. 

Extracorporeal Membrane Oxygenation Machine Market Report Scope

Global Extracorporeal Membrane Oxygenation Machine Market Report Segmentation

This report forecasts revenue growth at global, regional, & country levels as well as provides an analysis on the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the extracorporeal membrane oxygenation machine market report on the basis of component, modality, patient type, application, and region.

• Component Outlook (Revenue, USD Million, 2018 - 2030)

  • Pumps

  • Oxygenator

  • Controllers

  • Cannula

  • Accessories

• Modality Outlook (Revenue, USD Million, 2018 - 2030)

  • Veno-Arterial

  • Veno-Venous

  • Arterio-Venous

• Patient Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Neonates

  • Pediatric

  • Adult

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Respiratory

    • Neonates

    • Pediatric

    • Adult

  • Cardiac

    • Neonates

    • Pediatric

    • Adult

  • ECPR

    • Neonates

    • Pediatric

    • Adult

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway 

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand 

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait